| Similar Articles |
|---|
 |
The Motley Fool
December 27, 2007
Brian Lawler |
A New Era at Millennium? Millennium Pharmaceuticals submits a supplemental New Drug Application with the FDA to expand the use of lead drug Velcade to patients with multiple myeloma.   |
The Motley Fool
October 30, 2006
Brian Lawler |
Millennium Is So Last Century The drug company released its third-quarter results last week, and there is not much particularly exciting therein. None of its drug candidates is in late-stage testing and all are years away from approval, except for follow-on indications for Velcade. Investors, take note. |
The Motley Fool
July 27, 2007
Brian Lawler |
Millennium Waits for the Future Millennium Pharmaceutical has eleven new drugs in the pipeline for the future, but for today all they have is lower revenue and higher expenditure guidance. |
The Motley Fool
April 30, 2007
Brian Lawler |
The Future Millennium Isn't So Exciting Biotech drugmaker Millennium Pharmaceuticals released its quarterly financial results. Investors, take note. |
The Motley Fool
October 9, 2006
Brian Lawler |
Much-Needed Publicity for Millennium Millennium Pharmaceuticals' cancer-fighting drug Velcade is set to gain exposure for a new treatment. Investors, take note. |
The Motley Fool
December 15, 2003
W.D. Crotty |
Millennium Celebration Millennium took just four and a half years to push Velcade from first human dose to FDA approval, and the company has financial muscle most biotechnology companies only dream about. |
The Motley Fool
January 8, 2007
Brian Lawler |
Millennium Looks Ahead Shares of the biopharmaceutical company ended the year more than 10% higher, despite the presence of increased competition for its cancer treatment Velcade and all sorts of attempted merger and acquisition activity within the company. The pharmaceutical foresees a mixed 2007. |
Pharmaceutical Executive
July 1, 2006
Deborah Dunsire |
Thoughtleader: Targeted Expansion Millennium Pharmaceuticals' CEO discusses what's ahead for the company, its success through partnerships, and why it believes it can lead the pack in targeted therapeutics. |
The Motley Fool
January 31, 2008
Brian Lawler |
Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug. |
BusinessWeek
July 21, 2003
Gene G. Marcial |
A Rosier Millennium? Jump into Millennium Pharmaceuticals stock. That's the word from some Millennium trackers who think its recent fall -- from 17.20 in mid-June to 14 on July 1 -- was unwarranted. It is now at 15. |
The Motley Fool
November 6, 2007
Brian Lawler |
It's All About VELCADE at Millennium Millennium Pharmaceuticals announces a strong quarter of financial results. |
The Motley Fool
February 18, 2004
Jeff Hwang |
Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule. |
The Motley Fool
July 26, 2010
Brian Orelli |
Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Pharmaceutical Executive
February 1, 2014
William Looney |
Takeda' Oncology Taskmaster Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge; and a lead position in the hotly contested search to make cancer a treatable disease. |
Bio-IT World
August 13, 2003
Branca et al. |
Discovery Surges and Tools Deliver Market Compass for Q2 finds consolidation among drug discovery companies continuing, but market caps rising. |
Bio-IT World
January 13, 2003
Malorye Branca |
Charting a Course After the Genome A quarterly feature looks at the financial numbers in the bio-IT industry. |
Bio-IT World
August 18, 2004 |
Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
April 2, 2008
Brian Lawler |
Seattle Genetics Bulks Up Its Pipeline Seattle Genetics biopharmaceutical clinical studies are firing on all cylinders. |
Chemistry World
July 2, 2013
Sonja Hampel |
Thalidomide teams-up with turmeric to kill myeloma cells Cancer researchers in the US and China have combined the turmeric spice pigment curcumin and the drug thalidomide to create hybrid compounds that can kill multiple myeloma cells. |
The Motley Fool
June 6, 2007
Brian Orelli |
Cure Your Cancer or Your Money Back Janssen-Cilag, a subsidiary of Johnson & Johnson, has recently offered to refund the cost of Velcade to the British National Health Service if the patient fails to respond to its multiple myeloma drug. Drug-company investors need not worry about these kinds of deals. |
PC Magazine
September 21, 2004 |
Doom 3 The original death match shooter has been revitalized for the new millennium, but it keeps things personal with a four-player-only mode that is true to the original game. |
The Motley Fool
July 26, 2007 |
United Community Banking Away Profits: Fool by Numbers At United Community Banks it has been a very good second quarter. |
The Motley Fool
March 1, 2005
Rich Smith |
Dow Recharges Millennium Cell A new partnership with Dow Chemical may not do much for Millennium Cell investors, but it beats letting their company run out of juice. |
The Motley Fool
March 23, 2006
Seth Jayson |
Family Dollar Blowout: Fool by Numbers The deep discounter released second-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
